2025 in Review: Anthrax Preparedness
ARLINGTON, VA - The American Biodefense Action Coalition (ABAC), a coalition of Americans concerned about the threat of biological warfare, today applauded the significant Congressional and Executive Branch action that took place throughout 2025 in support of preparedness for the threat of Anthrax. These developments occurred following concerns of a previously-planned reduction in Anthrax antitoxin stockpiles.
A summary of the significant Congressional momentum in 2025:
H.R. 2707’s Introduction & Momentum: H.R. 2707, the Protecting American Families & Servicemembers From Anthrax Act, requiring the Strategic National Stockpile to fully meet its Anthrax antitoxin requirement, was introduced by Reps. Don Davis (D-NC) and Jen Kiggans (R-VA). H.R. 2707 now has the support of 18 Members of Congress - 13 Republicans and 5 Democrats - including senior Members of House Armed Services, Energy & Commerce, China-Select, Homeland Security, and Intelligence Committees.
U.S. House of Representatives NDAA Report Language: A version of H.R. 2707 was included in the U.S. House of Representatives’ accompanied report to the National Defense Authorization Act, requiring the U.S. Government to advance interagency efforts that ensures a 10-year-plan for the sustainment of Anthrax antitoxin countermeasures.
Congressional Oversight: A bipartisan letter was sent in October 2025 to the leadership of the Administration for Strategic Preparedness and Response (ASPR), ensuring the ASPR advance a 10-year-plan for the stockpiling and sustainability of Anthrax antitoxin countermeasures. Signatories included Reps. Don Davis (D-NC), Jen Kiggans (R-NC), Jack Bergman (R-MI), Chrissy Houlahan (D-PA), Greg Murphy (R-NC), and Pat Harrigan (R-NC).
U.S. Senate LHHS Appropriations Report: The FY26 U.S. Senate LHHS Appropriations Report that advanced out of Committee includes report language requiring the SNS to develop a plan to mitigate shortfalls of medical countermeasures, specifically noting gaps in the Anthrax treatment portfolio.
Congressional Testimony: In December 2025, Rep. Don Davis (D-NC) testified before the U.S. House Energy & Commerce Committee on the importance of passing H.R. 2707, citing growing concerns of Anthrax weaponization from America’s adversaries.
A summary of Executive Branch momentum in 2025 can be found below:
Executive Order 14155: President Trump’s Executive Order 14155, dated January 20, 2025, specifically requires the National Security Council to advance efforts to fortify biosecurity.
Executive Order 14366: President Trump’s Executive Order 14366, dated August 13, 2025, specifically requires the ASPR and the SNS to ensure the sustainment of the domestic Industrial Base for medical countermeasures, and to ensure the stockpiling and resilience of domestic producers of medical countermeasures and other essential medications.
President Trump’s UN General Assembly Remarks: President Trump called on nations globally to end their biological weapons development programs, in his September 2025 UN address.
Given the overwhelming support for ensuring America’s defense from the Anthrax threat, ABAC calls on the ASPR to swiftly take action to meet the on-going Congressional and Executive Branch directives.
ABAC applauds the tremendous efforts of President Trump and the United States Congress to advance Anthrax defense in 2025. ABAC expects that 2026 will promise to be another transformational year in bolstering America’s defenses from the Anthrax threat.